Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BMO Capital Cuts Albertsons Price Target By 7%

BMO Capital analyst Kelly Bania lowered the price target on Albertsons Companies Inc (NYSE:ACI) to $24 from $26 and maintained an Underperform rating…
byShivani Kumaresan
July 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • BMO Capital analyst Kelly Bania lowered the price target on Albertsons Companies Inc (NYSE:ACI) to $24 from $26 and maintained an Underperform rating on the shares.
  • The analyst thinks there is a higher chance that consumer headwinds and signs of trade-down on value could hamper the company’s earnings.
  • The analyst also warned about the impact of a possible wave of wage investments for unionized grocers on Albertsons’ earnings.
  • Price Action: ACI shares are trading lower by 0.26% at $26.35 on the last check Friday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CymaBay Therapeutics Announced Collaboration with Kaken Pharmaceutical to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis; Kaken to Make Upfront Payment To Cymabay Of ~$34M Plus Milestone Payments Up To ~$128.4M And Royal…

By Charles Gross
January 8, 2:17 PM
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis ("PBC").

CBAY